Astellas buys OSI Pharma for $4 billion in cancer push

Posted by Reuters: Business News on May 17, 2010

TOKYO (Reuters) – Astellas Pharma , Japan’s No.2 drugmaker, agreed to buy U.S. biotech OSI Pharmaceuticals for $4 billion in cash in a sweetened bid that will add OSI’s blockbuster cancer drug Tarceva to its line-up.